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Abstract Nitric oxide (NO) is often used to treat heart
failure accompanied with pulmonary edema. According to
present knowledge, however, NO donors are contraindi-
cated when systolic blood pressure is less than 90 mmHg.
Based on recent findings and our own clinical experience,
we formulated a hypothesis about the new breakthrough
complex lifesaving effects of NO donors in patients with
cardiac arrest and cardiopulmonary resuscitation therapy. It
includes a direct hemodynamic effect of NO donors med-
iated through vasodilation of coronary arteries in cooper-
ation with improvement of cardiac function and cardiac
output through reversible inhibition of mitochondrial
complex I and mitochondrial NO synthase, followed by
reduction in reactive oxygen species and correction of
myocardial stunning. Simultaneously, an increase in vas-
cular sensitivity to sympathetic stimulation could lead to an
increase in diastolic blood pressure. Confirmation of this
hypothesis in clinical practice would mean a milestone in
the treatment for cardiac arrest and cardiopulmonary
resuscitation.
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Introduction
Research of over two decades has shown nitric oxide (NO)
to be a ubiquitous modulator of biological phenomena from
cell signal to effector and from physiology to pathophysi-
ology. The involvement of NO in cardiovascular biology
has contributed significantly to our understanding of com-
plex disease states including atherosclerosis, systemic and
pulmonary hypertension, endotoxic shock, preeclampsia,
cardiomyopathy, myocardial infarction (MI), and cardiac
allograft rejection. The dichotomy of effector function
represents the ‘‘double-edged sword’’ of NO in biological
systems. The balance between cytostatic and cytotoxic
effects of NO may lie in the tissue concentration of NO
produced, the particular NO synthase (NOS) isoform acti-
vation, and the complex interaction with other free radicals
such as superoxide [1, 2]. All four NOS isoforms - endo-
thelial NOS (eNOS), neuronal NOS (nNOS), inducible
NOS (iNOS) and mitochondrial NOS (mtNOS) - have been
shown to be present in the human myocardium and may be
activated in response to hypoxia or ischemia. Studies of
experimental myocardial infarction have shown an
increased expression of iNOS, eNOS, and NO production in
the heart, together with increased plasma concentrations of
nitrate and nitrite, the oxidation products of NO. The iso-
form specific amount of NO generated may account, in part,
for physiological versus pathological effects of NO; low
concentrations are associated with cytostasis and high
concentrations with cytotoxicity. A further explanation for
the dichotomous effects of NO may lie in its complex
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interaction with reactive oxygen species (ROS), which is
particularly pertinent in the context of ischemia–reperfu-
sion. NO can interact in direct equimolar concentrations
with superoxide to form peroxynitrite. The greater avail-
ability of superoxide may favor peroxynitrite production
and toxicity. Thus, superoxide may be an important rate-
limiting factor determining the protective versus toxic
effects of NO. Although the interaction of NO with ROS is
very complex, this simple relation may explain why despite
the cytoprotective effects of NO against ischemia–reper-
fusion injury reported in the majority of animal studies,
several authors reported cytotoxicity [3–7].
Mechanisms of nitric oxide-mediated cardioprotection
The precise mechanisms whereby NO protects the myo-
cardium against ischemia–reperfusion injury remain
unclear. NO or its second messenger, cyclic guanosine
monophosphate (cGMP), has been shown to exert a number
of actions that would be expected to be beneficial against
myocardial ischemia–reperfusion injury, including inhibi-
tion of Ca2? influx into myocytes [8], antagonism of the
effects of b-adrenergic stimulation [9], reduction in myo-
cardial oxygen consumption [10, 11], and opening of sar-
colemmal ATP-sensitive K? (K?ATP) channel [12, 13]. NO
protects the ischemic myocardium by stimulation of cyclo-
oxygenase-2 (COX-2) activity with consequent production
of cytoprotective prostanoids such as prostaglandin (PG) E2
and PGI [14]. This mechanism was identified by Shinmura
et al. in the setting of late preconditioning, where inhibition
of iNOS was found to abrogate prostanoid synthesis,
whereas inhibition of COX-2 did not affect iNOS activity
[14] but resulted in loss of protection, indicating that COX-2
activity is driven by iNOS-derived NO and is obligatorily
required for iNOS to exert its cardioprotective effects [15].
Nitric oxide has also been suggested to protect against
lethal ischemia–reperfusion injury by preventing the
impairment of endothelium-dependent coronary vasodila-
tion [16] and by reducing the ‘‘no reflow’’ phenomenon
[17], the infiltration of leukocytes [18], the release of
cytokines, and expression of adhesions molecules [19].
NO and cardiomyocyte function
As mentioned above, NO via cGMP dose-dependently
inhibits phosphodiesterase (PDE) and/or activates protein
kinase G (PKG). At low NO/cGMP concentrations (in lM
range), inhibition of PDEIII activity or direct activation of
adenylyl cyclase [20] with subsequently increased cyclic
adenosine monophosphate (cAMP) concentration and pro-
tein kinase A (PKA) activity increases cardiomyocyte
function [22]. Additional mechanisms by which low
NO/cGMP concentrations might increase cardiomyocyte
function relate to a direct activation of ryanodine receptors
or voltage-operated calcium channels [21]. At higher NO/
cGMP concentrations (in lM range), activation of PKG
inhibits voltage-dependent calcium channels [21, 22] and
decreases myofilament calcium responsiveness by phos-
phorylation of troponin I [23]. While a higher NO/cGMP
concentration also suppresses the increase in regional
myocardial function during b-adrenergic stimulation [24],
most likely by directly inhibiting ryanodine receptors,
pharmacological blockade of endogenous NOS-dependent
NO synthesis in pigs did not impact on adrenergic respon-
siveness [25]. Thus, only at high concentrations might NO/
cGMP directly reduce cardiomyocyte function.
NO and antioxidant activity
NO has been reported to be a free radical scavenger [26].
The antioxidant capacity of plasma was found to be doubled
by the administration of NO donors. Moreover, these con-
centrations of the NO donors prevented reperfusion-induced
mucosal injury, which has been shown to be mediated in
large part by reactive oxygen metabolites [27]. A mecha-
nism for superoxide anion scavenging by NO has not been
clearly delineated. It is possible that production of NO in
amounts exceeding local production of superoxide anion
leads to accelerated decomposition of peroxynitrite to
nitrate and nitrite, thus reducing tissue exposure to perox-
ynitrite and to the hydroxyl radical that can be formed from
peroxynitrite. In addition to acting as a superoxide scav-
enger, NO may also have the ability to prevent superoxide
production. Clancy et al. reported that NO could inhibit
superoxide production from neutrophils by directly inhib-
iting nicotinamide adenine dinucleotide phosphate-oxidase
(NADPH oxidase) [28].
NO and anti-inflammatory effects
NO has for a long time been linked to the modulation of the
immune response and effects on cell-mediated immunity
may have a role in cytoprotection. High doses of NO have
been shown to modulate the production of interleukin 12
negatively, thus reducing the T-helper cell 1 immune
response [29]. In the context of inflammation, the endothe-
lium plays a particularly important role in regulating the
passage of blood and plasma constituents from the vascu-
lature to the interstitium. The ability of these constituents to
pass between adjacent endothelial cells is regulated by
contractile elements within the endothelial cells. Contrac-
tion of these elements results in an increase in endothelial
paracellular permeability. Thus, endothelial contraction
contributes to edema formation in the context of inflamma-
tion. Various chemical mediators can increase endothelial
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permeability and promote edema formation, including his-
tamine, leukotriene C4, and platelet-activating factor. The
actions of NO on vascular permeability appear to be pre-
dominantly anti-inflammatory; that is, NO diminishes
endothelial permeability. NO donors have been found to
reduce edema formation in various experimental models,
while inhibitors of NO synthesis can exacerbate edema
formation [30, 31]. Infiltration of leukocytes to a site of
injury or infection is a hallmark feature of inflammation, and
one that can be profoundly influenced by NO. NO has been
shown to inhibit the expression of the b-2 adhesion mole-
cules on neutrophils [32]. Inhibition of NO synthesis results
in a marked increase in leukocyte adherence to the endo-
thelium [33], while adherence of leukocytes to the vascular
endothelium in response to stimulation with a chemotactic
factor can be markedly suppressed by NO donors [34, 35].
NO can also down-regulate neutrophil aggregation and
secretion and may protect the neutrophil from damage
induced by the potent reactive oxygen metabolites that it is
capable of producing [36, 37]. NO can inhibit transcriptional
events by inhibiting the transcription factor nuclear factor
kappa B (NF-kB) [38]. NO appears to play an important role
in regulation of adhesion molecules on the luminal surface of
the endothelium. NO reduces P-selectin expression, while
inhibitors of NO synthase elicit an increase in P-selectin
expression and a corresponding increase in leukocyte
adherence to the endothelium [33, 39]. As in the case of
relaxant effects of NO on vascular smooth muscle, down-
regulation of P-selectin expression by NO is mediated via
soluble guanylate cyclase/ cGMP [40].
NO and reduction in intracellular calcium overload
It is well known that accumulation of intracellular calcium
(Ca2?) is lethal to cardiomyocytes [41, 42]. The conse-
quence of excessive accumulation of intracellular Ca2?
during the early reperfusion phase leads to numerous sec-
ondary effects, including stimulation of contractile ‘‘rigor’’
[43, 44], mitochondrial dysfunction, over-stimulation of
(Ca2?)-dependent enzymes, opening of the mitochondrial
permeability transition pore [45], and induction of proa-
poptotic processes. NO reduces calcium influx into
cardiomyocytes by modulating sarcolemmal Na?/H? ion
channel, mitochondrial Ca2?-ATP-ase, and by modulating
ryanodine receptor type 2 (RyR2) Ca2? release channels on
the sarcoplasmatic reticulum. Therefore, NO reduces
intracellular calcium overload and its complications.
NO and apoptosis
In isolated cardiomyocytes and hearts, high NO concen-
trations (lM range) induce necrosis and apoptosis [46, 47].
The amount of necrosis and apoptosis critically depends on
the energetic situation of the cardiomyocytes, with apop-
tosis favored at preserved ATP pools [48]. While the
development of necrosis following NO application appears
to be independent of cGMP, the development of apoptosis
involves cGMP and subsequently activation of mitogen-
activated protein kinases and transcription factors [46, 49,
50]. Most interestingly, the development of apoptosis fol-
lowing application of a NO donor is decreased, once
cardiomyocytes or isolated hearts have been subjected to a
preceding period of ischemia–reperfusion [46, 47], possi-
bly by a diminished response of guanylyl cyclase to NO.
NO can also directly inhibit apoptosis. Proposed mecha-
nisms include the suppression of caspase 1 and 3 activity
by NO-induced S-nitrosation; GMP-mediated suppression
of calcium-mediated apoptotic cell death; and induction of
the cytoprotective stress proteins heat shock protein 70 and
heat shock protein 32 [51].
Mitochondrial targets of cardioprotection and their
interaction with NO
Mitochondria are the major site of cellular energy and
production of adenosine triphosphate (ATP). The respira-
tory chain accepts electrons from nicotinamide dinucleotide
(NADH)/H and flavine adenine dinucleotide (FADH)/H and
transports them over 4 complexes ultimately onto oxygen,
creating a proton gradient that then drives ATP production.
Apart from ATP production and its role in cell function and
survival, mitochondria are decisive elements for cell death
by apoptosis, autophagy, and necrosis and, conversely, are
targets for protection from cell death by NO-mediated
mechanisms.
Respiratory chain
The respiratory chain releases small amounts of ROS pre-
dominantly by complex I under physiological conditions
[52]. Partial uncoupling of the respiratory chain protects
against ischemia–reperfusion injury, supporting the impor-
tance of mitochondrial ROS for cardioprotection. During
early reperfusion, ROS formation from various sources,
including the respiratory chain, is largely augmented. At
subcellular level, NO was shown to modulate mitochondrial
function through reversible and irreversible interactions
with respiratory chain complexes. Mitochondrial complexes
I and III are major sources of pathological ROS production.
Reversible inhibition of complex I has been proposed as a
mechanism to achieve cardioprotection. The protective
effects of complex I inhibition were described for different
NO donors and observed during ischemic preconditioning in
animal models [53–55]. Physiological concentrations of NO
inhibit cytochrome oxidase (complex IV) in a reversible
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manner, in competition with oxygen. Reversible inhibition
of complex I by S-nitrosation (NO-mediated modification of
thiols) is cardioprotective by limiting excess ROS formation
during reperfusion [56]. The reversible interaction may play
an important part in the physiological regulation of mito-
chondrial function by reducing oxygen consumption with-
out causing ATP depletion. This may be beneficial during
ischemia [53, 57, 58]. Reversible suppression of mito-
chondrial respiration was shown to explain myocyte adap-
tation to chronic hypoxia without compromising cell
survival or accelerating ATP depletion. Mitochondrial
dysfunction is a critical component of ischemia–reperfusion
injury, which is characterized by dissipation of the mem-
brane potential, ATP depletion, induction of the transient
mitochondrial permeability, and mitochondrial calcium
overload. A number of data suggest that NO-induced
depolarization of the mitochondrial membrane potential
protects cardiomyocytes by reducing mitochondrial calcium
overload during hypoxia–reoxygenation injury [54, 55, 59].
Connexin 43
Connexin 43 is present at the inner mitochondrial mem-
brane of cardiomyocytes. [60]. Reduction in connexin 43
abolishes the cardioprotection by ischemic preconditioning
[61] but not postconditioning [62]. ROS formation and
cardioprotection in response to diazoxide depend on
mitochondrial connexin 43, suggesting that its function is
to regulate the gating of mitochondrial K?ATP channels
[63]. Mitochondrial connexin 43 is targeted by several
protein kinases, including glycogen synthase kinase 3
(GSK-3) [62].
Mitochondrial potassium-ATP channel
The K?ATP channel in the inner membrane is inhibited by
ATP and activated by protein kinase C (PKC)-e and PKG.
The exact molecular composition of the K?ATP channel and
the participation of the sulfonylurea receptor subunit 2A
(SUR2A) and the potassium channel proteins Kir6.1 and 6.2
remain elusive. A purified inner membrane fraction,
including the adenine nucleotide transporter and succinate
dehydrogenase, confers K?ATP channel activity and is tar-
geted by K?ATP agonist/antagonist drugs [64]. Mitochon-
drial K?ATP channels are causally involved in ischemic
preconditioning and postconditioning [65, 66]. Sasaki et al.
found that NO directly activates mitochondrial K?ATP
channels and potentiates the ability of diazoxide to open
these channels [67]. Bell et al. demonstrated that nitric
oxide can mediate cardioprotection in a dose-dependent
fashion by an effect that may be related to mitochondrial
membrane potential. Both cardioprotection and changes
of mitochondrial membrane potential are sensitive to
5-hydroxy decanoate (5-HD), selective inhibitor of K?ATP
channel, and the cardioprotection appears independent of
free radical synthesis [68]. Thus, on the basis of these
results, it appears that the mitochondrial K?ATP channel is a
pivotal target for the protective effects of nitric oxide.
Mitochondrial calcium overload is pathognomic of irre-
versible ischemia-reperfusion injury - the calcium paradox
[69, 70]. Interestingly, mitochondrial K?ATP channel
openers attenuate the calcium paradox [71] and limit cal-
cium accumulation in mitochondria by altering mitochon-
drial calcium homeostasis [72]. Given that opening of the
mitochondrial permeability transition pore (PTP) is asso-
ciated with triggering of apoptotic cell death cascades and
that high calcium leads to opening of the PTP [73, 74], the
finding that low-dose exogenous nitric oxide attenuates both
the calcium paradox and the opening of the PTP is of great
interest [75]. Since exogenous nitric oxide has been dem-
onstrated to increase the open probability of mitochondrial
K?ATP channels [67], it is attractive to postulate that car-
dioprotective low-dose nitric oxide is initial mediated via
the mitochondrial K?ATP channel.
Mitochondrial permeability transition pore
The mitochondrial PTP is a large-conductance megachannel
putatively constituted by the voltage-dependent anion chan-
nel in the outer membrane, the adenine nucleotide transporter
in the inner membrane, and cyclophilin D in the matrix [76].
Under physiological conditions, mitochondrial PTP is pre-
dominantly in a closed state. Although PTP opening is
strongly inhibited by acidosis during ischemia, it is favored
by ATP depletion, oxidative stress and high intramitochon-
drial Ca2? concentrations, conditions all concurrent during
myocardial reperfusion [77].
PTP opening is associated with mitochondrial swelling,
outer membrane rupture, and the release of proapoptotic
factors such as cytochrome c from the intermembrane
space. Once released, cytochrome c activates caspase 9,
which in turn activates caspase 3. This protease mediates
the proteolytic cleavage of a range of proteins responsible
for the rearrangement of the cytoskeleton, plasma mem-
brane, and nucleus that are characteristic of apoptosis [78,
79]. Opening of the mitochondrial PTP is considered a key
event in cell death after ischemia–reperfusion [74, 80].
Inhibition of PTP opening is cardioprotective, but transient
opening of PTP is required for cardioprotection [81].
Mitochondrial PTP opening depends on NO. Low levels of
NO prevent PTP opening, whereas high NO levels accel-
erate PTP opening and cytochrome c release [56]. Part of
the apparent paradox may be methodological in nature.
Subsarcolemmal and interfibrillar mitochondria differ in
their morphology and function. It is possible that sarco-
lemmal mitochondria serve a signaling function, whereas
386 Heart Fail Rev (2014) 19:383–390
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interfibrillar mitochondria are targets of damage and pro-
tection from it.
These were the many positive effects of NO in ische-
mia–reperfusion (IR) injury. But on the other hand, NOS
enzymes have also been shown to play a deleterious role in
IR injury. For example, iNOS-deficient mice were shown
to have lower mortality and enhanced left ventricular
contractility when compared with wild-type mice after
coronary occlusion [82]. Also, exposing mitochondria to
high concentrations of NO (lM) has been shown to initiate
mitochondrial PTP opening [75]. These results, along with
other studies, have defined NO as a dual-faced molecule in
IR injury, which contributes to both cardioprotective and
deleterious signaling pathways within the myocardium. In
this regard, understanding how to deliver NO (i.e., timing,
concentration, location) may facilitate beneficial thera-
peutic exploitation of NO signaling in IR injury, while
minimizing the deleterious effects of NO. With respect to
these experimental results, it seems to indicate that the
protective effects of low-dose nitric oxide in the whole
heart are not mediated by their generation, which appears
contrary to a previous report using exogenous nitric oxide
used as a trigger of preconditioning [83] and also post-
conditioning. The discrepancy would suggest that exoge-
nous nitric oxide as a cardioprotective agent mediates
protection via different mechanisms to those recruited by
transient exposure of the heart to nitric oxide to trigger
preconditioning; preconditioning requires up-stream sig-
naling to result in a cardioprotective ‘‘memory.’’ In the
paradigm presented in this report, nitric oxide is free to act
directly upon end-effector targets downstream of precon-
ditioning- and postconditioning recruited pathways, with-
out the need to recruit preconditioning memory, and
therefore no need for free radicals to achieve this state.
In 2011, Minamishima et al. found that NO inhalation at
40 ppm for 23 h starting 1 h after successful cardiopul-
monary resuscitation markedly improved myocardial and
neurological function and survival rate 10 days after car-
diac arrest in mice [57]. Based on these experimental and
clinical results, we formulated hypothesis that NO donors
may be very beneficial in acute heart failure with cardio-
genic shock and cardiopulmonary resuscitation treatment.
Theoretical basis for the value of NO donation
in ischemia–reperfusion injury
According to current recommendations, intravenous nitro-
glycerine is contraindicated when systolic blood pressure
(BP) is below 90 mmHg. Hemodynamic properties of
vasodilators, and NO donors in particular, were extensively
studied in the 1970s and 1980s, although usually not in
terminal patients with no BP. Franciosa et al. [84] reported
that intravenous sodium nitroprusside increased cardiac
output and decreased wedge pressure in 15 patients with
acute MI and elevated left ventricular filling pressure. Their
BP was not allowed to fall below 95 mmHg, with the
average drop in systolic BP at only 26 mmHg. Similar
results were achieved in severe heart failure secondary to
ischemic or dilated cardiomyopathy. In 1984, Bayley et al.
[85] evaluated incremental doses of intravenous nitroglyc-
erine in patients with left ventricular failure. The maximal
hemodynamic benefit, in terms of decrease in wedge pres-
sure and increase in cardiac index, was obtained at 160 lg/
min, which represented the highest dose tested. Cotter et al.
[86] randomized patients with pulmonary edema into
cohorts receiving isosorbide dinitrate at 3-mg bolus
administered intravenously every 5 min versus traditional
treatment using low doses of isosorbide, furosemide, and
morphine. BP was not allowed to drop below 90 mmHg.
Mechanical ventilation was required in 13 % of the high-
dose nitrate group and in 40 % of the traditional group. MI
occurred in 17 and 37 %, respectively [86]. The poor
prognosis of cardiac arrest is driven primarily by brain and
heart injury. Except for hypothermia, no beneficial postre-
suscitation therapies have emerged since the description of
cardiopulmonary resuscitation (CPR) 50 years ago. The
present postresuscitation care is largely supportive. The role
of NO donors would be of great importance in this setting.
In man, myocardial dysfunction is common in cardiac arrest
and strongly associated with mortality, yet it may be made
ultimately reversible. The molecular mechanisms of myo-
cardial stunning after cardiac arrest remain unknown, but
loss of excitation–contraction coupling is believed to result
from ROS injury and calcium-mediated proteolysis. Based
on the above findings, we formulated the hypothesis of the
complex action of NO donors in cardiac arrest and acute
heart failure and cardiogenic shock treatment. On the one
hand, NO donors may increase cardiac output produced by
rapid vasodilatation in a heart operating at the extreme of
the Frank-Starling curve. In heart failure with or without
acute MI, vasodilators have over a long time been shown to
decrease left ventricular filling pressure and systemic vas-
cular resistance while increasing the cardiac index. The
more severe the failure, the more beneficial the effect of
vasodilators. On the other hand, NO donors by inhibiting
mitochondrial complex I and reducing ROS production may
mitigate cardiac stunning and improve systolic function,
cardiac output, and ultimately prove lifesaving. NO also
stabilizes the mitochondrial membrane and directly or
indirectly inhibits proapoptotic processes. It is tempting to
consider the possibility that NO regulates also calcium
levels in the mitochondria by modulating the activity of the
mitochondrial calcium uniporter, a mechanism protecting
against lethal mitochondrial calcium overload. Further-
more, exogenous administration of NO donor could lead to
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reversible inhibition of mtNOS in particular, and thus to a
reduction in peroxynitrite formation. These mechanisms act
together in synergy and are complementary. Vasodilatation
of the coronary artery ensures adequate myocardial perfu-
sion. Furthermore, reversible inhibition of mitochondrial
complex I blocks production of ROS in reperfusion. We
assume that the synergy of these mechanisms is able to
improve systolic function and consequently increase sys-
tolic BP. This can be explained by the so-called paradoxical
increase in systolic blood pressure after bolus quantity of
NO donors. Of course, according actually facts NO donors
in the peripheral parts of the circulation cause also vaso-
dilation. On the other side, we assume that NO increases
vascular sensitivity to noradrenaline and sympathetic
stimulation. In this way, we explain the increase and sta-
bilization of diastolic BP after bolus administration of NO
donors in cardiopulmonary resuscitation.
Conclusions
In conclusion, the action of NO donors in cardiac arrest
may be summarized in three points: (1) a direct hemody-
namic effect mediated through vasodilation of coronary
arteries in cooperation with, (2) direct effect on improving
cardiac function and cardiac output through above men-
tioned molecular mechanisms, and (3) at the same time, an
increase in vascular sensitivity to sympathetic stimulation
could lead to increase in diastolic blood pressure. This
hypothesis must of course be verified by several clinical
studies. If confirmed, it may mean a major breakthrough in
the treatment for cardiac arrest and cardiopulmonary
resuscitation that would result not only in better effects on
cardiac function but prove even lifesaving.
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